Arcus Biosciences Launches Public Offering of Common Stock to Fund Clinical Development

Key Facts

Arcus Biosciences announced the commencement of an underwritten public offering of its common stock to fund its operations and therapeutic development. According to a statement via Business Wire, all shares in the offering are being sold by the company, which also granted underwriters a 30-day option to purchase additional shares.

The company is seeking to raise capital to support its clinical-stage biopharmaceutical development focused on cancer and immune diseases. RCUS closed at $23.75 on October 20, 2026, after trading between a low of $20.81 and a high of $24.70 during that session.